Cipla Secures U.S. Rights for Keytruda Biosimilar in Deal With Qilu

Cipla Ltd (via Invagen Pharmaceuticals) has finalized an exclusive licensing agreement with Qilu Pharmaceutical to bring a biosimilar version of Keytruda to the United States.

Reader Takeaway: The deal expands Cipla’s U.S. oncology portfolio by leveraging Qilu’s manufacturing for Cipla's commercial distribution.

What just happened

Cipla’s subsidiary, Invagen Pharmaceuticals Inc., has partnered with China’s Qilu Pharmaceutical to supply and commercialize QL2107, a biosimilar of the blockbuster oncology drug Keytruda (pembrolizumab). Under the agreement, Qilu will oversee the R&D, regulatory registration, and supply of the drug, while Cipla USA Inc. will handle all commercial operations within the United States.

Why this matters

Keytruda is one of the highest-revenue oncology drugs globally. Entering the biosimilar space for such a major asset represents a significant strategic pivot for Cipla. By partnering with Qilu, which has a track record of 58 U.S. FDA ANDA approvals, Cipla is utilizing an established manufacturing partner to bypass the heavy capital expenditure typically required for internal biosimilar development, while playing to its strength in U.S. commercial network management.

Risks to watch

As with all biosimilar products, the primary risk is regulatory. The commercial launch of QL2107 is entirely contingent on receiving approval from the U.S. FDA. The timeline for these filings and the subsequent approval process can be lengthy and uncertain, which could impact the projected revenue trajectory for the company's biosimilar division.

What to track next

Shareholders should look for upcoming BSE filings regarding specific regulatory milestones, FDA filing dates, and any updates on the clinical development timeline for QL2107.